LAVERDIA® (verdinexor tablets) is an oral prescription medication for
the treatment of lymphoma in dogs. As the first FDA-approved oral
treatment for canine lymphoma, it uses a selective inhibitor of nuclear
export (SINE) mechanism to help target cancer cells. The convenient
twice-weekly dosing schedule provides an oral treatment option for
veterinary oncology patients.

▪First FDA-approved oral treatment for lymphoma in dogs
▪Selective inhibitor of nuclear export (SINE) designed to target cancer
cells
▪Convenient twice-weekly oral dosing regimen
▪Available in 2.5 mg, 10 mg, and 50 mg tablet strengths
▪Affordable oral treatment option for canine lymphoma